Xencor, Inc. $XNCR Stock Position Increased by BVF Inc. IL

BVF Inc. IL increased its position in shares of Xencor, Inc. (NASDAQ:XNCR) by 160.3% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 7,133,720 shares of the biopharmaceutical company’s stock after buying an additional 4,393,579 shares during the period. Xencor comprises about 3.7% of BVF Inc. IL’s portfolio, making the stock its 8th biggest position. BVF Inc. IL owned 9.99% of Xencor worth $109,217,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in the company. Primecap Management Co. CA increased its stake in shares of Xencor by 1.4% during the third quarter. Primecap Management Co. CA now owns 10,675,022 shares of the biopharmaceutical company’s stock worth $125,218,000 after buying an additional 147,700 shares during the period. Vanguard Group Inc. increased its stake in shares of Xencor by 0.9% during the fourth quarter. Vanguard Group Inc. now owns 7,165,450 shares of the biopharmaceutical company’s stock worth $109,703,000 after buying an additional 61,692 shares during the period. State Street Corp increased its stake in shares of Xencor by 22.7% during the fourth quarter. State Street Corp now owns 4,507,254 shares of the biopharmaceutical company’s stock worth $69,006,000 after buying an additional 833,423 shares during the period. Geode Capital Management LLC increased its stake in shares of Xencor by 1.4% during the fourth quarter. Geode Capital Management LLC now owns 1,752,918 shares of the biopharmaceutical company’s stock worth $26,842,000 after buying an additional 24,093 shares during the period. Finally, Legal & General Group Plc increased its stake in shares of Xencor by 2.8% during the fourth quarter. Legal & General Group Plc now owns 1,308,088 shares of the biopharmaceutical company’s stock worth $20,027,000 after buying an additional 35,088 shares during the period.

Analysts Set New Price Targets

A number of analysts recently weighed in on XNCR shares. Wall Street Zen lowered shares of Xencor from a “hold” rating to a “strong sell” rating in a research note on Saturday, May 9th. Weiss Ratings restated a “sell (d-)” rating on shares of Xencor in a research note on Friday, March 27th. JPMorgan Chase & Co. upped their target price on shares of Xencor from $13.00 to $14.00 and gave the stock a “neutral” rating in a research note on Monday, May 11th. Barclays upped their target price on shares of Xencor from $26.00 to $27.00 and gave the stock an “overweight” rating in a research note on Thursday, February 26th. Finally, Zacks Research downgraded Xencor from a “hold” rating to a “strong sell” rating in a report on Wednesday, May 6th. Six equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $24.50.

Xencor Stock Up 4.8%

Shares of XNCR opened at $12.78 on Thursday. The stock has a 50 day moving average price of $12.10 and a 200 day moving average price of $12.98. The company has a market capitalization of $947.51 million, a price-to-earnings ratio of -5.58 and a beta of 0.92. Xencor, Inc. has a 52-week low of $6.92 and a 52-week high of $18.69.

Xencor (NASDAQ:XNCR) last announced its quarterly earnings results on Wednesday, May 6th. The biopharmaceutical company reported ($1.71) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.96). The business had revenue of $4.52 million during the quarter, compared to analyst estimates of $27.86 million. Xencor had a negative net margin of 177.10% and a negative return on equity of 28.77%. The business’s revenue for the quarter was down 86.2% compared to the same quarter last year. During the same period last year, the company earned ($0.66) earnings per share. On average, equities analysts anticipate that Xencor, Inc. will post -3.84 EPS for the current fiscal year.

About Xencor

Xencor, Inc is a clinical-stage biopharmaceutical company focused on the design and development of engineered protein therapeutics for the treatment of autoimmune diseases, cancer and neurological disorders. The company applies its proprietary XmAb® platform to manipulate antibody structure and function, creating molecules with enhanced immune engagement and extended half-life. Xencor’s research programs span a range of therapeutic modalities, including monoclonal antibodies, bispecific antibodies and cytokine-based fusion proteins.

The XmAb® platform enables precise modification of the Fc region to augment key properties such as receptor binding, effector function and pharmacokinetics.